Fora Capital, LLC Genmab A/S Transaction History

Fora Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$34.88 - $43.22 $145,414 - $180,184	-4,169 Reduced 27.58%	10,947 $413,000
Q4 2022 Feb 08, 2023	BUY	$33.8 - $47.06 $510,920 - $711,358	15,116 New	15,116 $640,000
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $107,198 - $125,697	-2,580 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $84,830 - $114,990	2,580 New	2,580 $105 Million
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $224,912 - $322,965	-7,274 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $191,559 - $231,965	5,691 Added 359.51%	7,274 $295,000
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $301,896 - $353,109	-9,129 Reduced 85.22%	1,583 $58 Million
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $214,775 - $363,029	10,712 New	10,712 $363 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.